Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer by Sonnenblick, Amir et al.
Spotlight on breast cancer
Sonnenblick et al. BMC Medicine  (2015) 13:177 
DOI 10.1186/s12916-015-0416-2RESEARCH ARTICLE Open AccessConstitutive phosphorylated STAT3-associated
gene signature is predictive for trastuzumab
resistance in primary HER2-positive breast cancer
Amir Sonnenblick1, Sylvain Brohée1, Debora Fumagalli1, Delphine Vincent1, David Venet1, Michail Ignatiadis1,2,
Roberto Salgado1, Gert Van den Eynden3, Françoise Rothé1, Christine Desmedt1, Patrick Neven4, Sibylle Loibl5,
Carsten Denkert6, Heikki Joensuu7, Sherene Loi8, Nicolas Sirtaine9, Pirkko-Liisa Kellokumpu-Lehtinen10,
Martine Piccart2 and Christos Sotiriou1,2*Abstract
Background: The likelihood of recurrence in patients with breast cancer who have HER2-positive tumors is
relatively high, although trastuzumab is a remarkably effective drug in this setting. Signal transducer and activator
of transcription 3 protein (STAT3), a transcription factor that is persistently tyrosine-705 phosphorylated (pSTAT3) in
response to numerous oncogenic signaling pathways, activates downstream proliferative and anti-apoptotic
pathways. We hypothesized that pSTAT3 expression in HER2-positive breast cancer will confer trastuzumab resistance.
Methods: We integrated reverse phase protein array (RPPA) and gene expression data from patients with
HER2-positive breast cancer treated with trastuzumab in the adjuvant setting.
Results: We show that a pSTAT3-associated gene signature (pSTAT3-GS) is able to predict pSTAT3 status in an
independent dataset (TCGA; AUC = 0.77, P = 0.02). This suggests that STAT3 induces a characteristic set of gene
expression changes in HER2-positive cancers. Tumors characterized as high pSTAT3-GS were associated with
trastuzumab resistance (log rank P = 0.049). These results were confirmed using data from the prospective, randomized
controlled FinHer study, where the effect was especially prominent in HER2-positive estrogen receptor (ER)-negative
tumors (interaction test P = 0.02). Of interest, constitutively activated pSTAT3 tumors were associated with loss of PTEN,
elevated IL6, and stromal reactivation.
Conclusions: This study provides compelling evidence for a link between pSTAT3 and trastuzumab resistance in
HER2-positive primary breast cancers. Our results suggest that it may be valuable to add agents targeting the STAT3
pathway to trastuzumab for treatment of HER2-positive breast cancer.
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Trastuzumab is a remarkably effective therapy for pa-
tients with HER2-positive breast cancers, both in the
metastatic and adjuvant settings [1–3]. However, not all
women with tumors expressing high levels of HER2 re-
spond to trastuzumab. Several potential mechanisms to* Correspondence: christos.sotiriou@bordet.be
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creativecommons.org/publicdomain/zero/1.0/explain trastuzumab resistance have been proposed, in-
cluding loss of PTEN, excessive signaling through the
insulin-like growth factor-I receptor, or expression of
p95HER2, a truncated form of the HER2 receptor that has
kinase activity but lacks the extracellular trastuzumab-
binding domain [4, 5].
Signal transducer and activator of transcription pro-
teins (STATs) are latent cytoplasmic proteins that form
functional dimers with each other when activated by
tyrosine phosphorylation, upon which they translocate
to the nucleus to regulate the expression of genes by
binding to specific elements within gene promoters.ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ous oncogenic signaling pathways [6]. Indeed, constitu-
tive activation of STAT3 has frequently been detected in
diverse human cancer cell lines and tissues, including
breast cancers [6]. Many studies have suggested that
STAT proteins could participate in oncogenesis by up-
regulating genes that encode inhibitors of apoptosis
(Mcl-1, Bcl-xl), cell-cycle regulators (cyclins D1/D2, c-
Myc), and inducers of angiogenesis (VEGF) [7–9]. More-
over, STAT3 has also been shown to play a role in the
pathogenesis of breast cancer through its positive effects
on invasion, stem cell expansion, and modulation of the
environment [10].
Activated or tyrosine phosphorylated STAT3 (pSTAT3)
is found in approximately 50 % of breast cancers, with the
highest expression levels identified in the leading edge of
tumors, in areas of lymphovascular invasion and in axillary
lymph nodes [10–13]. Additionally, STAT3 has been
shown to mediate immune suppression by inhibiting ex-
pression of pro-inflammatory cytokines and chemokines
necessary for immune cell activation [14]. The role of
pSTAT3 as a negative regulator of immune cell-mediated
antitumor responses and as an oncogenic driver led us to
hypothesize that pSTAT3 expression might be a predictor
of resistance to trastuzumab therapy in patients with
HER2-positive breast cancer.
Methods
Patients and samples
For our study we used samples and data from three
main sources, Responsify, FinHer, and the TCGA reposi-
tory. The Responsify dataset (as part of the FP7 EU con-
sortium; grant number 278659; [15]) is composed of 108
HER2-positive early stage breast cancer samples treated
with adjuvant trastuzumab provided by the Institut Jules
Bordet and the Katholieke Universiteit Leuven. HER2
was defined by an immunohistochemistry (IHC) of 3+
or a positive result on fluorescence in situ hybridization
(FISH) for HER2 amplification (HER2: Chr17 ratio ≥2).
Gene expression data were available for 94 patients,
reverse-phase protein lysate microarrays (RPPA) for 51
patients, and clinical outcome data for all patients. The
clinical pathological characteristics of patients in the
Responsify dataset are provided in Additional file 1:
Table S1A. Study participants provided written informed
consent to allow further research analyses to be carried
out on their tumor tissue. Samples were accessed under
Leuven Hospital ethics approval No. S52903. Samples
were processed at the Institut Jules Bordet, Brussels,
Belgium, under ethics approval no. EC1750.
The FinHer dataset was derived from the trial of the
same name, a multicenter, phase 3, randomized breast can-
cer trial in the adjuvant setting that enrolled 1010 patients
(CONSORT diagram Additional file 2: Figure S1) [1]. Thewomen were randomly assigned to receive three cycles of
docetaxel or vinorelbine, followed by three cycles of fluoro-
uracil, epirubicin, and cyclophosphamide. Out of the 1,010
patients, 232 patients with HER2-positive breast cancers
were further randomized to nine weeks of trastuzumab or
to no trastuzumab. Overall, 202 of 232 HER2-positive tu-
mors had sufficient good quality RNA for gene expression
analysis.
The clinical pathological characteristics of the patients
with HER2-positive tumors who also had available gene
expression data (n = 202) were compared with the gen-
eral series (n = 231) (Additional file 3: Table S1B). The
patients with gene expression data were representative
of the entire population, with no substantial differences
in patient and tumor characteristics identified between
the two groups (Additional file 3: Table S1B). Study par-
ticipants provided written informed consent to allow
further research analyses to be carried out on their
tumor tissue. Gene expression profiling from the breast
tumor samples was approved by the Helsinki University
institutional review board (permission HUS 177/13/03/
02/2011).
The primary end point of the FinHer study, distant
disease-free survival (DDFS), has been previously re-
ported to be superior for the trastuzumab-containing
arms after follow-up of 62 months [1]. The determin-
ation of hormone receptor status and HER2 expression
by IHC was required locally and was performed accord-
ing to the guidelines of each institution during the time
of the study. Samples were considered to be hormone
receptor-positive if their level of estrogen receptor (ER)
and/or progesterone receptor was ≥10 %. All patients
with hormone receptor-positive tumors received 5 years
of endocrine therapy. When HER2 expression was
scored as 2+ or 3+ (on a scale of 0, 1+, 2+, or 3+), the
number of copies of the HER2 gene was centrally deter-
mined by means of chromogenic in situ hybridization in
reference laboratories.
Gene expression arrays
The Responsify expression dataset was produced using the
Affymetrix HG-U133Plus2 platform at the J-C Heuson
Breast Cancer Translational Research Laboratory. Expres-
sion values were computed using the fRMA normalization
method (fRMA Bioconductor package) [16]. From the
Responsify dataset, a total of 97 samples corresponding to
95 unique patients were processed. Appropriate quality as-
sessments were conducted on the resulting files, and 94
samples passed quality assurance for further analysis. The
Responsify data is available at: [16].
As mentioned above, from the FinHer HER2 samples,
gene mRNA expression data was produced from 202
samples. All samples were re-evaluated to ensure the
tumor was present. RNA was extracted from formalin-
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Gene expression was measured using Affymetrix U219
GeneChips™ as per Affymetrix protocols on 96 well
plates at AROS applied biotechnology A/S, Denmark.
Affymetrix expression data were normalized using the
RMA approach, followed by a batch effect correction
(Affy and SVA package of the Bioconductor suite) [17].
For both the Responsify and FinHer datasets, when
multiple probe sets mapped to the same official gene
symbol, we computed the average value.
In the TCGA repository, HER2-positive breast cancers
were analyzed based on the RPPA phosphorylation levels
[18]. Patients with a Z score greater than 0.2 (STAT3 high)
or less than −0.2 (STAT3 low) in the overall distribution
were selected for comparison using the cBioPortal web ap-
plication [18] from Memorial Sloan Kettering Cancer
Center [19]. mRNA expression data were also downloaded
from the TCGA repository. In all cases, the downloaded
data were TCGA level 3 [18]. The data (RPPA and gene ex-
pression) were uploaded to the GenePattern web software
of the Broad Institute [20]. Patient data were analyzed for
differential gene expression using the Comparative Marker
Selection tool comparing STAT3 high and STAT3 low
genes for each subtype (P = 0.001, fold ≥1). The TCGA
data has open access through few portals and permission
to access the TCGA data was not required.
The differences in platforms and methods across the dif-
ferent datasets, including the TCGA dataset that was used
for external validation, are summarized in Additional file 4:
Table S2 and Additional file 5: Figure S2D.
Reverse phase protein array (RPPA)
The protein levels of the Responsify cohort were assessed
in the laboratory of Gordon Mills at MD Anderson Cancer
Center (Houston, TX) using RPPA, as previously described
[18]. The following procedures were performed for the
current RPPA core: tumor lysates were two-fold-serial di-
luted for five dilutions (from undiluted to 1:16 dilution)
and arrayed on nitrocellulose-coated slide in 11 × 11 for-
mat. Samples were probed with antibodies by amplifica-
tion approach and visualized by DAB colorimetric
reaction. Slides were scanned on a flatbed scanner to pro-
duce 16-bit tiff image. Spots from tiff images were identi-
fied and the density was quantified by Array-Pro Analyzer.
Relative protein levels for each sample were determined
by interpolation of each dilution curves from the
“standard curve” (supercurve) of the slide (antibody).
All the data points were normalized for protein loading
and transformed to linear value designated as “Linear
after normalization”; 243 slides for 211 unique anti-
bodies were stained and analyzed on Array-Pro then by
supercurve R ×64 2.15.1. There were 14 sets of repli-
cated antibodies and three negative controls for second-
ary antibodies among 243 slides. A quality control testwas performed for each antibody staining (slide), in
which a score above 0.8 indicates good antibody stain-
ing (all antibodies used in the present study).
Computation of the pSTAT3 gene signature
To develop a predictive gene signature score, we com-
puted the scalar product of the coefficient of the genes in
the signature and the gene expression values (pSTAT3-
GS). Fifty-one HER2-positive samples in the Responsify
dataset with both available gene expression and RPPA data
were evaluated. For the pSTAT3 RPPA assay, we consid-
ered two sample groups with clear “up” and “down” pro-
tein expression by splitting the samples to upper and
lower quartile of the expression mean (Additional file 5:
Figure S2A). To identify the genes that were differently
expressed in the two groups, we performed gene expression
analysis using a Student t-test (Welch adaptation with ro-
bust estimators of dispersion and central tendency) com-
paring high versus low tumors (false discovery rate (fdr)
≤0.05; Additional file 5: Figure S2B). To compute the
expression of the pSTAT3-GS using available expression
datasets, we defined a signature score: Let S be a gene
signature composed of n genes (s1, …, sn) presenting a co-
efficient (–1 or 1, depending on the down-regulation or up-
regulation, respectively) and let E be the set of expression
values of the genes of S in one expression experiment.
The pSTAT3-GS score (Sigscore) is derived by com-
puting the sum of the products of the gene coefficient in
the module (Si) by the corresponding gene expression
value (ei) according to the following formula:
Sigscore ¼
Xn
i¼1
ei  Si
Histological stromal reactivation evaluation
Evaluation of stromal reactivation was performed simul-
taneously by two pathologists (RS, GVdE) blinded to the
molecular data. The methodology and cut-offs were pre-
defined before the evaluation. Stromal reactivity was de-
fined as scar-like, desmoplastic tissue containing a higher
proportion of reactive myofibroblasts compared to the
normal stroma of the breast, which does not contain re-
active myofibroblasts. For the assessment of the stromal
reactivity score, the proportion of the stromal area con-
taining reactive myofibroblasts in proportion to the whole
stromal area of both the invasive tumor area and the full
slide (containing reactive stroma and normal non-reactive
stroma) was evaluated. Tumors were divided into three
groups on the basis of the amount of reactive stroma;
Score 1: 0–30 % of myofibroblasts in 10 High Power-
fields; Score 2: 31–60 % of myofibroblasts in 10 High
Power fields, and score 3: 61–100 % of myofibroblasts in
10 High Power fields.
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For the outcome analysis, patients were scored accord-
ing to the pSTAT3-GS. The primary outcome for the
Responsify dataset was disease free survival (DFS) and
for the FinHer, DDFS, which was defined by the time
interval between the date of randomization and the date
of first cancer recurrence outside of the ipsilateral/locor-
egional region or to death, whichever occurred first.
Patients alive at the last visit without documented evi-
dence of distant metastases were censored. Associations
between the pSTAT3-GS, pSTAT3, and clinical patho-
logical parameters or other proteins were investigated
with a t-test, and the correlation was estimated using a
linear regression and a Pearson index. Survival curves
were generated according to the Kaplan–Meier method,
and survival distributions were compared using the log-
rank test. Univariate and multivariate models were com-
puted with Cox proportional hazards regression. The
possible interaction with trastuzumab treatment was
tested using a likelihood ratio test between Cox survival
models adjusting or not for the trastuzumab treatment.
Analyses were performed using the R statistical suite to-
gether with the Bioconductor ‘genefu’ package. The abil-
ity of the pSTAT3-GS to predict the pSTAT3 RPPA
status of the patients was assessed with receiver operat-
ing characteristic (ROC) curves. RPPA pSTAT3-positive
(mean +1SD) and pSTAT3-negative (mean +1SD) were
used as cut-offs in HER2-positive breast cancers from
the TCGA (N = 81). ROC curves were computed using
the pROC library of the R statistical suite.
Significant associations between the signature scores
and the stromal reactivation status were assessed using
one-tailed Mann–Whitney tests comparing the signature
scores in samples with low stromal reactivation (+) com-
pared to samples with moderate or high (++/+++) stro-
mal reactivation.
Our data were reported according to the essential ele-
ments of the “Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK)” [21].
Results
pSTAT3 HER2-positive breast cancers are associated with
a distinct gene expression profile
RPPA of pSTAT3 (tyrosine 705) was performed on 51
primary HER2-positive breast cancers using the Respon-
sify dataset, which is composed of 108 HER2-positive
early stage breast cancer patients treated with adjuvant
trastuzumab (Additional file 1: Table S1A). No signifi-
cant correlation was found between pSTAT3 status and
any classic clinicopathological features (Additional file 1:
Table S1A).
To determine whether pSTAT3 signaling pathway acti-
vation was associated with specific transcriptional
changes, we compared gene expression profiles obtainedfrom pSTAT3-positive (upper quartile) and pSTAT3-
negative (lower quartile) samples using a two-sample t-
test (Additional file 5: Figure S2A). Overall, 123 genes
were significantly (positively or negatively) (fdr ≤0.05) and
differentially expressed between pSTAT3-positive and
pSTAT3-negative tumors, suggesting a distinct gene ex-
pression pattern associated with pSTAT3 signaling path-
way activation (Dataset Additional file 5: Figure S2B,
Additional file 6: Table S3).
To assess whether these genes could predict the phos-
phorylation status of STAT3, we computed a pSTAT3
gene expression signature score (pSTAT3-GS) according
to their respective gene expression values. As expected,
we found a positive significant correlation between the
pSTAT3 RPPA and the pSTAT3-GS expression levels in
the whole Responsify dataset, from which the signature
was developed (r = 0.62, P = 0.19e-6).
To independently validate the ability of the pSTAT3-GS
to determine pSTAT3 proteomic status in HER2-positive
breast cancer, we used the TCGA cohort of patients
with HER2-positive breast cancer in which gene expres-
sion and RPPA data are available [19]. As shown in
Additional file 5: Figure S2C, the ability of the pSTAT3-
GS to classify tumors based on their pSTAT3 proteomic
status was significant, validating its predictive perform-
ance (area under the curve [AUC] of the receiver oper-
ating curve, 0.77; P = 0.02).
A gene set enrichment analysis [20] showed enrich-
ment with Jak-STAT-regulated genes (P = 0.006; fdr =
0.14), as well as with genes associated with cell surface
signal transduction and protein kinase activity. This sug-
gests that the pSTAT3-GS captures pSTAT3 signaling
pathway activation (Additional file 7: Table S4).
Association of the pSTAT3-GS with clinical outcome in
patients with HER2-positive breast cancer treated
with trastuzumab
Since pSTAT3 has been reported to play a role in the
pathogenesis of breast cancer through its positive effects
on invasion, its modulation of the microenvironment, and
its role as a negative regulator of immune cell–mediated
antitumor responses, we hypothesized that pSTAT3 ex-
pression might influence response to trastuzumab therapy.
To address this, we first correlated the phosphorylation
status of pSTAT3 with clinical outcome using the Respon-
sify dataset, in which all patients received trastuzumab in
the adjuvant setting and for which we had RPPA available
data (N = 51). No association was found between pSTAT3
protein levels and clinical outcome (Fig. 1a–c).
Since the numbers were small, we sought to interro-
gate whether the pSTAT3-GS, which mirrors STAT3
pathway activation, could predict clinical outcome on
the same dataset involving a larger number of patients
with available gene expression data (N = 94). Of note,
Fig. 1 pSTAT3 RPPA and P-STAT3-GS survival analysis. a–c Kaplan–Meier curves according to pSTAT3 RPPA status in all patients (a), ER-negative
(b), or ER-positive patients (c) for whom RPPA data was available in the Responsify dataset. d–f Kaplan–Meier curves according to pSTAT3-GS
status in all patients (d), ER-negative (e), or ER-positive patients (f) for whom the gene expression data was available in the Responsify dataset
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pSTAT3-GS, and hence all the survival analyses were un-
biased in their estimate of its performance. Interestingly,
high pSTAT3-GS (dichotomized at the median) was sig-
nificantly associated with poor outcome. This observation
was mainly driven by the ER-negative subgroup (DFS, log
rank P = 0.039 for ER-negative; Fig. 1d–f).
These observations were further validated in an inde-
pendent dataset of patients treated in the prospective
FinHer trial, in which patients were randomized to tras-
tuzumab in the adjuvant setting (Additional file 3: Table
S1B, CONSORT diagram S1). In this validation series,
high pSTAT3-GS was associated with a lack of benefit
from trastuzumab in the ER-negative subgroup when
compared to low pSTAT3-GS (DDFS, P = 0.01; Fig. 2).
Cox univariate and multivariable analysis of the
pSTAT3-GS in the FinHer study confirmed – with a sig-
nificant interaction test of P = 0.02 (Table 1) – that the
pSTAT3-GS could provide independent predictive in-
formation for patients with ER-negative breast cancer
who had been treated with trastuzumab. Overall, our
data suggest that pSTAT3 pathway activation ispredictive for trastuzumab resistance in HER2-positive/
ER-negative breast cancer.
pSTAT3 is associated with PTEN loss and stromal
reactivation
Considering studies that have suggested that STAT3 could
participate in oncogenesis through the up-regulation of
genes encoding cell-cycle regulators (cyclins D1, c-Myc),
and a recent report of in vitro data suggesting that PTEN
signaling may be associated with trastuzumab resistance
[21], we sought to investigate whether there was any rela-
tionship at the protein level between pSTAT3, PTEN, and
other proteins regulated by STAT3 in our clinical samples.
Using RPPA (211 proteins) in the Responsify dataset, we
found that pSTAT3 was negatively correlated with PTEN
(r = –0.4, fdr = 0.025) and positively correlated with stath-
min (r = 0.66, fdr = 0.03), a known marker of PTEN loss
[22] (Fig. 3a). Other significant positive correlations with
STAT3 included c-Myc (r = 0.39, fdr = 0.04), c-Kit (r =
0.66, fdr = 1.1e-5), and pEGFR (r = 0.52, fdr = 0.001).
pcMET and cyclin D1 were also positively correlated, but
did not pass the fdr ≤0.05 threshold. These data confirm
Fig. 2 The pSTAT3-GS has predictive significance in the independent randomized FinHer dataset. a–i Kaplan–Meier curves and forest plots of
signature status assessed in the FinHer dataset. Patients with pSTAT3-GS low (a, d, g) and pSTAT3-GS high (b, e, h) status according to trastuzumab
treatment in all patients (up), ER-negative only (middle), or ER-positive only (down). Forest plots according to pSTAT3-GS status in all patients (c),
ER- negative only (f), or ER-positive only (i). The plots indicate Cox regression hazard ratios and 95 % confidence intervals for trastuzumab benefit
for DDFS
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ticipates in oncogenesis through the up-regulation of
genes encoding cell-cycle regulators and that PTEN loss
may be associated with STAT3 activation.
Similar in silico analysis was performed at the gene
expression level with the pSTAT3-GS and signaturesTable 1 Cox univariate and multivariable analysis of pSTAT3-GS trea
DDFS prognostic value of pSTAT3-GS (No trastuzumab) DD
Univariate Multivariate Un
HR 95 % CI P HR 95 % CI P HR
All 0.77 0.53–1.13 0.18 0.77 0.52–1.13 0.19 0.9
ER– 0.67 0.39–1.15 0.14 0.66 0.39–1.12 0.12 2.2
ER+ 0.81 0.46–1.41 0.45 0.73 0.35–1.53 0.41 0.3
DDFS, Distant disease free survival; HR, Hazards ratio; CI, Confidence interval; ER, Es
For multivariate analysis, we considered the following variables: age, tumor size, gra
not used in the multivariate model). Interaction test for the multivariate analysisinvolving different signaling pathways and biological
processes [23]. As seen in Fig. 3b, the pSTAT3-GS was
mainly correlated with several stromal signatures, sug-
gesting a potential link between STAT3 expression and
stromal activation [24–27]. Of note, the pSTAT3-GS
was positively correlated with IL6 (r = 0.4, P = 4.72e−05),ted as a continuous variable, in the FinHer study
FS prognostic value of pSTAT3-GS (trastuzumab)
ivariate Multivariate P interaction
95 % CI P HR 95 % CI P
5 0.58–1.55 0.84 0.99 0.6–1.67 0.99 0.41
4 1.2–4.16 0.01 1.73 0.87–3.45 0.12 0.02
4 0.14–0.77 0.01 0.36 0.14–0.98 0.04 0.24
trogen receptor
de, nodal status, and ER status (when ER was used to stratify the groups it was
DB C
Fig. 3 pSTAT3 and pSTAT3-GS are associated with PTEN loss and stromal reactivation. a pSTAT3 is associated with PTEN loss. Heatmap representation
of the correlations between the RPPA values in the Responsify dataset. Cells are colored according to Pearson correlation coefficient values, with green
indicating positive correlation and red negative correlations. b pSTAT3-GS is associated with stromal reactivation. The heatmap reflects the hierarchic
clustering of pairwise correlations between different gene signatures in the Responsify dataset. Cells are colored according to Pearson correlation
coefficient values, with green indicating positive correlation and red negative correlations. c The heatmap of the top significantly enriched genes in
PAM50-identified patients with HER2-positive breast cancer annotated in the TCGA (P <0.001, fold >1), selected according to the high or low RPPA
expression level of pSTAT3. Cells are colored according to the gene expression values, with green indicating positive correlation and red negative
correlation. d pSTAT3-GS correlates with histological stromal reactivation. Histological sections showing breast tumors containing low (+), intermediate
(++), and high (+++) reactive stroma. Heatmap shows correlation of reactive stromal content with clinical pathological parameters (not significant) and
correlation with different gene signatures including stromal signature and pSTAT3-GS. * Negative correlation, P values were assessed using
Mann–Whitney test
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STAT3 is activated in breast cancer and a surrogate of
stromal reactivation (Additional file 8: Figure S3).
Supportive findings have been reported for the TCGA
dataset, in which HER2-positive breast cancers (based
on the PAM50 classification) were analyzed according to
their proteomic pSTAT3 status using the C-bio portal
web server [23]. pSTAT3-positive tumors were associ-
ated with stromal reactivation genes, including high ex-
pression of POSTN, SRPX2, ADAM12, DACT1, and
ADAMT6S (Fold >1, P <0.001; Fig. 3c).
Finally, to determine whether the pSTAT3-GS and
stromal signatures are associated with histological-
pathological stromal reactivation in HER2-positivepatients, we performed a blinded examination of the
Responsify frozen sections. For each sample, the pro-
portions of reactive stroma were evaluated by two pa-
thologists. Tumors were divided into three groups on
the basis of the amount of reactive stroma. Compari-
son of the histological data showed a positive associ-
ation of pSTAT3-GS and the different stromal gene
signatures with the amount of reactive stroma, while
the PTEN gene signature was negatively associated
with reactive stroma (Fig. 3d).
Overall, these data suggest that there is a potential link
between IL6-pSTAT3-PTEN loss, stroma reactivation,
and primary trastuzumab resistance in HER2-positive
primary breast cancers.
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In this study, we integrated RPPA and gene expression
data in order to interrogate the pSTAT3 signal transduc-
tion pathway in HER2-positive breast cancer. Specifically,
we sought to determine whether constitutive STAT3 path-
way activation could be responsible for primary resistance
to trastuzumab in this breast cancer type. We observed
that STAT3 phosphorylation was associated with a distinct
gene expression signature for STAT3 pathway activation,
and that this pSTAT3-GS was associated with trastuzumab
resistance in two independent datasets. To our knowledge,
ours is one of the first studies to use such a methodology
and to demonstrate that an RPPA-based gene expression
signature may reflect the proteomic activation status of
samples. One of the strengths of our study is that it used
gene expression data from a prospective clinical trial that
randomized patients with HER2-positive breast cancer to
receive treatment with or without trastuzumab.
Two recently published papers have used the general
same approach to link upstream signaling pathways to
downstream transcriptional response by exploiting RPPA
and mRNA expression in breast cancer, demonstrating
the robustness of this approach [28, 29].
A few studies have suggested that the activation of an
IL6 inflammatory loop through STAT3 mediates trastu-
zumab resistance in HER2-positive breast cancer by
expanding the cancer stem cell population and by pro-
moting epithelial-mesenchymal transition [21, 30, 31].
While these studies focused on pre-clinical acquired re-
sistance, in our study we provide evidence for primary
resistance in the clinical adjuvant setting. Moreover, we
identified STAT3 activation in a subset of patients with
PTEN loss, suggesting that novel strategies to block theFig. 4 Model. There is a potential link between IL6-pSTAT3-PTEN loss, strom
primary breast cancersSTAT3 pathway in combination with trastuzumab treat-
ment may be especially relevant in PTEN- deleted breast
cancer. The functional importance of IL6-STAT3 activa-
tion in PTEN-deleted HER2-positive breast cancer was
demonstrated in a study showing that the IL6R antibody,
alone or in combination with trastuzumab, decreased
the cancer stem cell population and inhibited develop-
ment of distant metastasis [21].
Recent studies have also highlighted the importance of
the tumor micro-environment, such as stromal cells, in
breast cancer prognosis and chemotherapy efficacy, par-
ticularly within the HER2-positive subgroup [24, 25, 27].
A mechanistic explanation for this phenomenon was
demonstrated in an article showing that the IL6-STAT3
pathway drives tumor progression through the stroma
and metastatic niche [31]. The positive correlation of
IL6 and pSTAT3 with stromal reactivation signatures in
our study supports the notion that this phenomenon oc-
curs in HER2-positive human specimens. Given that
levels of pSTAT3 are highest on the leading edge of tu-
mors in association with stromal and endothelial cells, it
is possible that samples that are pSTAT3-GS and stro-
mal signature-positive in our study contain more mater-
ial from the tumor edge or stroma. Indeed, the Yoshiara
stromal signature [26], which represents the fraction of
“normal” stromal cells in tumor tissue, also correlated
positively with the pSTAT3-GS. Nevertheless, pSTAT3-
GS still has the independent ability to predict resistance
to trastuzumab.
In our study, the predictive role of pSTAT3 was con-
fined to the ER-negative group while the ER-positive
group showed an opposite pattern, although not signifi-
cant. A possible explanation is that in the ER-positiveal reactivation, and primary trastuzumab resistance in HER2-positive
Sonnenblick et al. BMC Medicine  (2015) 13:177 Page 9 of 10group, different signal transduction pathways are in-
volved in the activation of STAT3. Indeed, in a recent
bioinformatics analysis, it was shown that low proliferat-
ing luminal breast cancers were much more likely to
possess a high pSTAT3 phenotype [29]. In addition, ana-
lyzing tissue microarrays from breast cancer patients
showed that pSTAT3 was associated with better prog-
nosis [12, 13, 32]. These observations suggest that
pSTAT3 may have different activators and targets in the
different breast cancer subtypes. Although we used pro-
spective randomized data in our study, the cohort from
the FinHer trial was relatively small. We therefore ac-
knowledge the need for further validation using a larger
number of patients.
Conclusions
Overall, we propose that the STAT3-stromal feed-forward
loop, which can be enhanced by PTEN loss, is predictive
of primary trastuzumab resistance (model; Fig. 4). If con-
firmed by future large prospective, randomized, controlled
studies, inhibiting the IL6-STAT3 pathway [33] may be a
valuable addition to trastuzumab treatment of primary
HER2-positive breast cancer, especially those that are
PTEN deficient.
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